Coronavirus cases in Texas surpass 900,000, state data shows

Coronavirus cases in Texas surpassed 900,000 over the weekend, according to state estimates.

As of Sunday, some 904,855 cases of the novel virus were reported in the Lone Star State, with more than 4,000 new cases reported on Sunday alone. Overall, more than 18,000 lives have been lost to COVID-19 in Texas, including the 53 new fatalities reported on Sunday. 

As of Sunday, some 904,855 cases of the novel virus were reported in the Lone Star State. (iStock)

As of Sunday, some 904,855 cases of the novel virus were reported in the Lone Star State. (iStock)

Additionally, more than 5,600 people are currently hospitalized with COVID-19 in the state. 

Texas is No. 2 in the nation for the most cases of the deadly virus reported in the past seven days, according to data from the Centers for Disease Control and Prevention (CDC). Illinois has reported the most in the past week, with 44,570 cases. Texas, meanwhile, has reported 42,480 cases in the past seven days, per the CDC. 

WAYS TO REDUCE ELECTION DAY STRESS, ANXIETY

The news comes as some states are encouraging, but not requiring, face masks at the polls ahead of Election Day on Tuesday. While officials in some states have said they will require voters who refuse to wear a mask to cast their vote either curbside or at an isolated location, a federal appeals court in Texas halted an order that would’ve required voters to wear a face mask while at the polls.

ARE POLL WORKERS AT AN INCREASED RISK FOR CORONAVIRUS?

As of Monday, the U.S. had tallied over 9.2 million cases of coronavirus and more than 231,000 deaths. A number of regions are seeing a surge in cases, as health officials have urged the public to refrain from letting so-called “coronavirus fatigue” set in, especially as the U.S. heads into flu season.

Fox News’ Alexandria Hein contributed to this report. 

Source Article

Read more

Global Herceptin Biosimilar Market to Surpass US$ 5.8 Billion by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global herceptin biosimilar market is estimated to be valued at US$ 1.3 billion in 2020 and is expected to exhibit a CAGR of 24.5 % over the forecast period (2020-2027).

Key Trends and Analysis of the Global Herceptin Biosimilar Market:

Key players are focused on obtaining product approvals to strengthen their position in the global herceptin biosimilar market. For instance, in June 2020, Roche Holding AG received the US Food Drug and Administration approval for Phesgo, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, a subcutaneous injection with combination with intravenous chemotherapy for treatment of early and metastatic breast cancer.

Moreover, key players are focused on launching products to strengthen their product portfolio in the global herceptin biosimilar market. For instance, in 2019, Samsungbioepis Co,.Ltd, received approval for its first oncology treatment, Ontruzant, a biosimilar of herceptin and received the approval from US Food Drug and Administration. The product is approved for treatment of metastatic HER2-overexpressing BC, early HER2-overexpressing BC, and advanced gastric cancer in the U.S.

Among regions, North America is expected to register highest growth rate due to the increasing prevalence of diseases such as colorectal cancer, breast cancer and lung cancer in women. The US National Library of Medicine’s report published in September 2020 stated that around breast, lung and colorectal cancer accounted for 50% of the overall cancer incidence in women in the US.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4258

Key Market Takeaways:

The global herceptin biosimilar market is expected to exhibit a CAGR of 24.5 % over the forecast period owing to the increasing prevalence of diseases such as gastric cancer and breast cancer in females and product approvals and launches in the global herceptin biosimilar market.

Competitive Landscape:

Key players operating in the global herceptin biosimilar market are Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4258

Market Segmentation:

  • Global Herceptin Biosimilar Market, By Indication:

    • Breast Cancer

    • Gastric Cancer

    • Others

  • Global Herceptin Biosimilar Market, By Distribution Channel :

    • Hospitals

    • Oncology Centers

    • Others

  • Global Herceptin Biosimilar Market, By Region:

    • North America

    • Latin America

      • By Country:

        • Brazil

        • Mexico

        • Argentina

        • Rest of Latin America

    • Europe

      • By Country:

        • Germany

        • U.K.

        • France

        • Italy

        • Spain

        • Russia

        • Rest of Europe

    • Asia Pacific

      • By Country:

        • China

        • India

        • Japan

        • Australia

        • South Korea

        • ASEAN

        • Rest of Asia Pacific

    • Middle East

      • By Country/Region:

        • GCC

        • Israel

        • Rest of Middle East

    • Africa

      • By Country/Region:

        • South Africa

        • Central Africa

        • North Africa

Related Market Intelligence Report:

Biosimilars Market, by Drug Class (Recombinant Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Insulin, Anticoagulants, Fusion Proteins, Erythropoietin, Monoclonal Antibodies, Follitropin, and Others), by Therapy Type (Oncology, Immunology, Hematology, Hormone Therapy, Metabolic Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Specialty Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) –

Read more

Global Blood Ketone Meter Market to Surpass US$ 486.3 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global blood ketone meter market is estimated to be valued at US$ 301.7 million in 2020 and is expected to exhibit a CAGR of 7.1% during the forecast period (2020-2027).

Key Trends and Analysis of the market:

The increasing number of product launches is expected to drive growth of the blood ketone meter market during the forecast period. For instance, in March 2020, EKF Diagnostics, the global in vitro diagnostics company, announced the launch of the U.S. FDA CLIA-waived β-ketone and glucose POC analyzer STAT-Site WB Analyzer in the U.S. market. This device is a new addition to its diabetes care portfolio in the U.S. The STAT-Site WB is a dual-use whole blood β-ketone and glucose meter for professional use in the management of diabetes.

Key manufacturers operating in the blood ketone meter market are engaged in developing more advanced products for the ease of diabetes patients. For instance, blood glucose & ketone testing meter by Foracare Inc., called FORA 6 Gtel, is a device that comes with 3G/4G connectivity. It can seamlessly transfer data to a TeleHealth System without the need for pairing it with a smartphone. With 5-Electrode Technology and strips made with gold, FORA 6 test strips ensure high accuracy and precision. It measures six parameters such as glucose, hematocrit, hemoglobin, β-ketone, total cholesterol, and uric acid in blood.

The global blood ketone meter market is expected to witness significant growth, owing to increasing partnerships and collaborations. For instance, in February 2020, the global diabetes nonprofit Beyond Type 1 announced a new collaboration with the National Association of School Nurses to create awareness about the warning signs of type 1 diabetes (T1D). With this new collaboration, awareness materials will be distributed to tens of thousands of school nurses nationally in the U.S. Moreover, Beyond Type 1 advocates will be enhancing efforts in ten target states: Arkansas, Connecticut, Florida, Massachusetts, New Jersey, North Carolina, Ohio, Oklahoma, Pennsylvania, and Texas.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/3498

Key Market Takeaways:

The global blood ketone meter market is expected to exhibit a CAGR of 7.1% during the forecast period (2020-2027), owing to the rising prevalence of type 1 diabetes worldwide. For instance, according to the National Diabetes Statistics Report by Centers for Disease Control and Prevention of 2017, around 1.25 million Americans suffered from type 1 diabetes and over 300,000 Canadians lived with type 1 diabetes in 2017. Furthermore, as per the same source, over 100,000 children in India and 50,000 children and adolescents in China were living with type 1 diabetes as of 2017.

Key players in the North America blood ketone meter market are focused on launching new products, which is expected to drive growth of the market during the forecast period. For instance, in March 2020, EKF Diagnostics launched the STAT-Site WB, a blood β-ketone and glucose meter in the U.S. The device is used for measuring ketone and for the management of diabetes.

Competitive Landscape:

Key players

Read more

Global coronavirus cases surpass the 40 million milestone

By Shaina Ahluwalia and Roshan Abraham

(Reuters) – Worldwide coronavirus cases crossed 40 million on Monday, according to a Reuters tally, as the onset of winter in the northern hemisphere fuelled a resurgence in the spread of the disease.

The Reuters tally is based on official reporting by individual countries. Experts believe the true numbers of both cases and deaths are likely much higher, given deficiencies in testing and potential under-reporting by some countries.

The Reuters data shows the pace of the pandemic continues to pick up. It took just 32 days to go from 30 million global cases to 40 million, compared with the 38 days it took to get from 20 to 30 million, the 44 days between 10 and 20 million, and the three months it took to reach 10 million cases from when the first cases were reported in Wuhan, China, in early January.

Record one-day increases in new infections were seen at the end of last week, with global coronavirus cases rising above 400,000 for the first time.

There were an average of around 347,000 cases each day over the past week, compared with 292,000 in the first week of October.

The United States, India, and Brazil remain the worst affected countries in the world. COVID-19 cases in North, Central, and South America represent about 47.27% or nearly half of global cases.

Around 247 cases are seen per 10,000 people in the United States. For India and Brazil, those numbers stand at 55 cases and 248 cases per 10,000 people respectively.

New cases are growing at over 150,000 a day in Europe, as many countries including Italy, Netherlands, Germany, Austria, Poland, Ukraine, Cyprus, and the Czech Republic have reported record daily increases in the number of coronavirus infections.

Europe currently accounts for over 17% of the global cases and nearly 22% of the deaths related to the virus worldwide.

Parts of the UK were put into lockdown as Prime Minister Boris Johnson bid to contain a second wave of infections through local measures.

France imposed curfews while other European nations are closing schools, canceling surgeries, and enlisting student medics.

President Donald Trump called for a big economic stimulus as U.S. infections surpassed eight million, with record spikes in several states.

States across the Midwest are seeing a rise in coronavirus cases, with new infections and hospitalizations rising to record levels.

India’s cumulative tally of coronavirus infections stood at 7.43 million on Saturday, with the number of active infections slipping below 800,000 for the first time in 1.5 months.

Iran, the Middle Eastern country hardest-hit by the coronavirus, extended restrictions and closures in the capital Tehran into a third week on Saturday as its death toll rose above 30,000.

Since the pandemic started, over 1.1 million people have died due to COVID-19, with the global fatality rate hovering around 2.8% of the total cases.

An official at the World Health Organization has said the global death toll from COVID-19 could double to 2 million

Read more

Global IV Infusion Bottle Seals & Caps Market to Surpass US$ 124.9 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global IV infusion bottle seals & caps market is estimated to be valued at US$ 104.3 million in 2020 and is expected to exhibit a CAGR of 2.6% over the forecast period (2020-2027).

Key Trends and Analysis of the Global IV infusion bottle seals & caps Market:

Key trends in the market include rising incidence of multiple sclerosis, arthritis, congestive heart failure, increasing launches of IV products, launch of new programs, and adoption of expansion strategies by the companies.

Rising incidence of chronic diseases such as multiple sclerosis, arthritis, congestive heart failure, and some types of immune deficiency disorders is expected to drive demand for infusion therapies, thereby contributing to significant growth of the IV infusion bottle seals & caps market. For instance, according to the National Center for Biotechnology Information (NCBI), 2020, in the year 2017, globally, around 126 million people suffered from ischemic heart disease (1,655 per 100,000). Furthermore, according to the World Federation of Hemophilia (WFH) 2018 statistics, around 440,000 people suffered from hemophilia, of which around 173,000 people were diagnosed with hemophilia A or B in 2017, globally.

Moreover, rising launches of IV products, in order to address the healthcare needs is the major factor, which is expected to drive the market growth over the forecast period. For instance, in June 2029, Eurolife Healthcare, a manufacturer and distributor specialty Infusion & pharmaceuticals, launched Discport and Lifeport IV products in India. These products are the replacement to the currently used polypropylene bottles (FFS bottles).

Moreover, market players are involved in launching new programs for patient safety, in order to increase the use of IV therapy and this is expected to drive the market growth. For instance, in April 2019, Becton, Dickson and Company (BD) launched a new program for patient safety in hospitals, called as PRIME (Preventing Risks of Infections and Medication Errors in IV Therapy). PRIME was developed in partnership with the Joint Commission International (JCI) for patient safety and aimed to address the challenges in a hospital setting regarding medical safety and infection prevention.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4238

Key Market Takeaways:

The global IV infusion bottle seals & caps market is expected to exhibit a CAGR of 2.6% over the forecast period, owing to facility expansion of pharmaceutical plastic packaging, which is expected to drive the market growth. For instance, in May 2018, Gerresheimer, a manufacturer of specialist packaging for drugs, announced the expansion of its facility in the Brazil. The new Gerresheimer Anápolis plant has commenced production in the Brazilian state of Goiás, for the production of the entire range of plastic containers from PP, PE, and PET, along with the corresponding closures and caps.

Competitive Landscape:

Key players operating in the global IV infusion bottle seals & caps market include Cardinal Health Inc., Jiangsu changjiang Lids, Taiwan Hon Chuan Enterprise, PrasadMeditech, Winfield Laboratories Inc., Datwyler HoldingAG, Wuxi Qitian Medical Technology Co., Ltd, Medline Industries Inc., RENOLITSE, and B. Braun Medical Inc.

Read more